Contribuições da disciplina de Semiologia e Semiotécnica na formação do enfermeiro / Contributions of the discipline of Semiology and Semiotechnics in nursing training

Introdução: na grade curricular da formação acadêmica em enfermagem é instituída a disciplina de semiologia e semiotécnica; onde a semiologia representa uma análise crítica e científica das sintomatologias relatadas pelo paciente, como também dos achados por toda equipe, enquanto a semiotécnica é compreendida como a execução de procedimentos técnicos estudados na teoria. Objetivo: relatar as experiências de acadêmicas de enfermagem acerca do ensino em semiologia e semiotécnica e suas contribuições na formação do profissional de enfermagem. Metodologia: trata-se de um estudo descritivo, observacional, do tipo relato de experiência, realizado por 4 acadêmicas matriculadas no período noturno do curso de enfermagem de um Centro Universitário particular, localizado na cidade de Maceió, estado de Alagoas. Resultados: as aulas, nesta instituição, são lecionadas em sala e também em laboratório de enfermagem, a disciplina acontece durante o 4º período, seguindo grade curricular padronizada, e tem como carga horária o total de 300 horas. Conclusões: durante o período observacional na instituição de ensino onde desenvolveu-se este estudo, foi possível identificar que a disciplina de semiologia e semiotécnica para os estudantes de enfermagm é capaz de contribuir na propagação da enfermagem de uma maneira vasta, indo desde o conhecimento da área assistencial até o papel social do enfermeiro; a realização de atividades com bonecos contribui de forma positiva no processo de aprendizagem, entretanto, apenas ela não é suficiente para sanar a insegurança nos momentos de contato direto com o paciente, visto que o ser humano possui sentimentos e reaçoes diversas

Análise da soroprevalência por teste rápido e ELISA de infecção por zika vírus em unidade prisional de Mato Grosso

A emergência do Zika vírus no Brasil entre os anos de 2015 e 2016, com graves morbidades relacionadas, suscitou a necessidade da disponibilidade de teste diagnóstico de qualidade. Neste contexto, buscou-se analisar a soroprevalência da infecção por Zika em uma unidade prisional feminina do estado de Mato Grosso através do teste rápido (Bahiafarma) e do Ensaio Imunossorvente por Ligação Enzimática de Captura de Anticorpos para Zika. Trata-se de um estudo transversal, com abordagem quantitativa, pautado em dados coletados em 2018, em que se coletou sangue periférico e procedeuse análise com duas estratégias diagnósticas: o teste rápido e o Ensaio Imunossorvente por Ligação Enzimática de Captura de Anticorpos para Zika. Em ambos os testes detectou-se sororreatividade para Zika, com excelentes concordâncias, ou seja, foi calculado o coeficiente Kappa e foram obtidos os valores de 1 para IgM e 0,86 para IgG. Além dos achados laboratoriais, foram relatados fatores de risco para a infecção, decorrentes das características intrínsecas ao ambiente prisional e do modo de vida das participantes. A descrição da soroprevalência dessa arbovirose será importante para direcionar as ações de prevenção e controle a serem implementadas pela vigilância epidemiológica

Os principais tipos e manifestações da Cirrose Hepática: uma atualização clínica

Introdução: A cirrose hepática é um processo patológica crônico, considerado a hepatopatia mais comum, definido como a conversão difusa morfoestrutural por nódulos de arquitetura anômalo envoltos por fibrose. Objetivou-se descrever os tipos mais relevantes de cirrose e suas devidas manifestações. Metodologia: Trata-se de uma revisão bibliográfica, fundamentada nas plataformas do SciELO, PubMed, Scopus, utilizando os termos “hepatical cirrhosis”, “liver disease” e “hepatocellular insufficiency” a qual através da revisão narrativa, abordou amplamente a respeito da contextualização da cirrose e as principais etiologias. Resultados e Discussão: Foi analisado que tal condição afeta qualquer faixa etária, sexo, etnia e independe da classe socioeconômica, mas as diversas etiologias impõem um perfil epidemiológico específico conforme a aparição. As principais origens abordam o tipo alcoólico, hepatite, aplicação crônica de alguns fármacos e esteatose gordurosa ou não. Ademais, estima-se que estas afetam a anatomofuncionalidade do órgão responsável por grande parte da homeostase, culminando em diversas manifestações clínicas.  Conclusão: A cirrose é uma consequência grave de fatores de base em estágio avançado, a qual devido ao seu curso geralmente silencioso culmina no desenvolvimento e progressão clínica. Neste contexto, a atenção aos fatores predisponentes como alimentação rica em lipídios, estilismo, negligência a exames de rotina, sedentarismo e obesidade contribuem constituem medidas eficazes de prevenção primária.&nbsp

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

Background: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Methods: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms. Results: ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≤ 18 years: 69, 48, 23; 85%), older adults (≥ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation: This international collaboration has allowed us to report reliable symptom data from the largest cohort of patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

LABORATÓRIO NACIONAL DE MÁXIMA CONTENÇÃO BIOLÓGICA (NB4): UM ESTUDO DAS PRIORIDADES DE USO CONFORME OS INTERESSES DA DEFESA

A implantação do primeiro laboratório de máxima contenção biológica (NB4) pelo governo federal brasileiro atende às necessidades de um grupo de dez ministérios, com demandas específicas de cada uma das partes interessadas. É importante distinguir quais são as atividades prioritárias ao emprego dessa instalação. Nesse sentido, o presente trabalho busca levantar as prioridades de utilização do laboratório NB4 pelo Ministério da Defesa (MD), para entender as peculiaridades das complexas estruturas de tais instalações e confrontar legislações de biossegurança, bioproteção e defesa biológica. A pesquisa é de natureza aplicada, com abordagem quantitativa e classificada como exploratória. As propostas de uso foram avaliadas por especialistas em biodefesa das Forças Armadas, que estabeleceram as prioridades por meio de questionários estruturados previamente, com possibilidade, ainda, de inclusão de novos usos potenciais da instalação. A análise estatística da consulta aos especialistas permitiu identificar dois grupos prioritários de ação: um relacionado à área de saúde e outro vinculado a temática científico-tecnológica direcionada à pesquisa. Assim, o grau de importância atribuído pelos especialistas às demandas para o laboratório NB4 reforça o comprometimento da Defesa e o valor estratégico da implantação do projeto

Laboratório Nacional de Máxima Contenção Biológica (NB4): um estudo das prioridades de uso conforme os interesses da defesa

<p>A implantação do primeiro laboratório de máxima contenção biológica (NB4) pelo governo federal brasileiro atende às necessidades de um grupo de dez ministérios, com demandas específicas de cada uma das partes interessadas. É importante distinguir quais são as atividades prioritárias ao emprego dessa instalação. Nesse sentido, o presente trabalho busca levantar as prioridades de utilização do laboratório NB4 pelo Ministério da Defesa (MD), para entender as peculiaridades das complexas estruturas de tais instalações e confrontar legislações de biossegurança, bioproteção e defesa biológica. A pesquisa é de natureza aplicada, com abordagem quantitativa e classificada como exploratória. As propostas de uso foram avaliadas por especialistas em biodefesa das Forças Armadas, que estabeleceram  as prioridades por meio de questionários estruturados previamente, com possibilidade, ainda, de inclusão de novos usos potenciais da instalação. A análise estatística da consulta aos especialistas permitiu identificar dois grupos prioritários de ação: um relacionado à área de saúde e outro vinculado a temática científico-tecnológica direcionada à pesquisa. Assim, o grau de importância atribuído pelos especialistas às demandas para o laboratório NB4 reforça o comprometimento da Defesa e o valor estratégico da implantação do projeto.</p&gt

Diminishing benefits of urban living for children and adolescents’ growth and development

Optimal growth and development in childhood and adolescence is crucial for lifelong health and well-being1–6. Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the height and body-mass index (BMI) of children and adolescents aged 5–19 years on the basis of rural and urban place of residence in 200 countries and territories from 1990 to 2020. In 1990, children and adolescents residing in cities were taller than their rural counterparts in all but a few high-income countries. By 2020, the urban height advantage became smaller in most countries, and in many high-income western countries it reversed into a small urban-based disadvantage. The exception was for boys in most countries in sub-Saharan Africa and in some countries in Oceania, south Asia and the region of central Asia, Middle East and north Africa. In these countries, successive cohorts of boys from rural places either did not gain height or possibly became shorter, and hence fell further behind their urban peers. The difference between the age-standardized mean BMI of children in urban and rural areas was <1.1 kg m–2 in the vast majority of countries. Within this small range, BMI increased slightly more in cities than in rural areas, except in south Asia, sub-Saharan Africa and some countries in central and eastern Europe. Our results show that in much of the world, the growth and developmental advantages of living in cities have diminished in the twenty-first century, whereas in much of sub-Saharan Africa they have amplified

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

BackgroundEstimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period.Methods22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution.FindingsGlobal all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations.InterpretationGlobal adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic